MatthewCurtisSolhjemMD

Radiation Oncology • Portland, OR

Physician

Join to view full profile

Dr. Solhjem is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Solhjem's full profile

Already have an account?

Office
4805 Ne Glisan St
Garden Level
Portland, OR 97213
Phone+1 503-215-6029

Fax+1 503-215-6387

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Chief Residency, Radiation Oncology, 2001 - 2005
University of North DakotaInternship, Transitional Year, 2000 - 2001
University of Minnesota Medical SchoolClass of 2000
University of MinnesotaBA, Psychology, 1993 - 1996

Certifications & Licensure

OR State Medical License 2005 - 2025
MN State Medical License 2001 - 2005
WI State Medical License 2004 - 2005
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Top Doctors Portland Monthly Magazine, 2013
CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013
Chief Resident Radiation Oncology, 2005
Moreton Fellowship Award for Radiation Oncology Research 2004
Resident of the Year Award University of North Dakota School of Medicine, 2001
Summa cum laude, Phi beta kappa University of Minnesota, 1996
Join now to see all

Clinical Trials

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Start of enrollment: 2008 Jun 01
Completed
Phase 3
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2010 Mar 31
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2010 Mar 01
Completed
Phase 2
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery Start of enrollment: 2011 Jan 01
Active, not recruiting
Phase 2
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Start of enrollment: 2011 Jun 01
Active, not recruiting
Phase 3
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Start of enrollment: 2010 Oct 14
Completed
Phase 1
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Start of enrollment: 2011 May 01
Active, not recruiting
Phase 3
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 3
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 2
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Start of enrollment: 2012 Apr 27
Completed
Phase 1
Chemoimmunotherapy and Radiation in Pancreatic Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1
Phase I Study of Safety and Immunogenicity of ADU-623 Start of enrollment: 2014 Jan 08
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

17 citations
Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression.
Matthew C. Solhjem, Brian J. Davis, Thomas M. Pisansky, Torrence M. Wilson, Lance A. Mynderse
Cancer Journal. 2004-11-01
35 citations
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely
The Lancet. Oncology. 2022-09-01
79 citations
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic...
Todd S. Crocenzi, Benjamin Cottam, Pippa Newell, Ronald F. Wolf, Paul D. Hansen
Journal for Immunotherapy of Cancer. 2016-08-16

Lectures

Radiation Therapy for Breast & Gynecologic Malignancies.
Providence St. Vincent Hospital
Lung Cancer and Radiation Therapy including Gamma Knife Stereotactic Radiosurgery.
Thoracic Oncology Symposium
Radiation Therapy for Prostate Cancer.
Providence St. Vincent Hospital
Post-Mastectomy Radiation Therapy for patients with 4 or more positive nodes.
American Association of Medical Dosimetry 3rd Annual Region I & Northwest Meeting
Everything you wanted to know about radiation therapy but were afraid ask.
Providence St. Vincent Medical Center
Join now to see all

MatthewCurtisSolhjemMD

Dr. Solhjem is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.